{"filings":[{"id":3055956,"accession_number":"0001104659-26-110241","cik":2094256,"company_name":"BEACON TOPCO, INC.","ticker":"CLYD","form_type":"8-K","filed_at":"2026-09-24T13:19:17+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Balomenib Phase 1b shows durable HbA1c improvement; Merger closing extended to Oct 31","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Merger closing date for Clywedog acquisition amended to Oct 31, 2026 (or earlier mutual agreement); End Date also Oct 31, 2026.","Phase 1b: placebo-adjusted HbA1c -0.77% at Week 12 (p<0.01) and -0.70% at Week 16 (p<0.05) after 3-week dosing.","OGTT: placebo-adjusted reductions in total glucose AUC 203 mmol·min/L (p=0.019), peak glucose 2.03 mmol/L (p=0.013), 2-hr glucose 2.46 mmol/L (p=0.010).","FPG reduced by 1.29 mmol/L (23 mg/dL) at Week 12 (p<0.05); no drug-related serious/severe AEs or discontinuations.","Phase 2a with 12-week treatment course expected to initiate in Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":"2026-09-24","daily_digest_url":"/daily/2026-09-24","daily_digest_rank":9},{"id":2916242,"accession_number":"0001104659-26-108353","cik":2094256,"company_name":"BEACON TOPCO, INC.","ticker":"CLYD","form_type":"8-K","filed_at":"2026-09-16T23:54:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Beacon Topco completes Barinthus Bio acquisition; launches $15M share tender offer","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition of Barinthus Biotherapeutics closed via UK scheme of arrangement effective Sept 9, 2026; Barinthus now wholly-owned subsidiary.","Cash tender offer launched Sept 15, 2026 to buy up to $15M of Beacon Topco common stock at $6.6609 per share, net to seller, no interest.","Amended and restated certificate of incorporation adopted effective Sept 9, 2026; amended and restated bylaws effective Sept 8, 2026.","Merger Agreement dated Sept 29, 2025, as amended Feb 22, 2026, governed the transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}